The premise of the paradox: examining the evidence that motivated GIPR agonist and antagonist drug development programs
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性,不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
JD Douros, SA Mowery, PJ Knerr
Journal of Clinical Medicine, 2025
mdpi.com
… There is a GIPR small molecule antagonist (Pfizer, PF-07976016) in phase 2 clinical trials
(NCT06717425) but little information is currently available regarding its structure, in vitro profile…

